Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of pirarubicin combined with hyaluronic acid for non-muscle invasive bladder cancer after transurethral resection: a prospective, randomized study

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objective

To verify the efficacy and safety of intravesical instillation of pirarubicin combined with hyaluronic acid after TURBT in non-muscle invasive bladder cancer patients.

Methods

We conducted a prospective study recruiting 127 eligible patients from 2008 to 2010. Patients were randomly assigned to Group A (pirarubicin combined with hyaluronic acid) and Group B (pirarubicin alone). Patients’ demographics, treatment efficacy on recurrence, visual analog scale score, and postoperative complications were evaluated and analyzed during observation.

Results

After the first month of intravesical chemotherapy, a perceptible relief of pelvic pain and urinary symptoms was detectable in Group A when compared with Group B (Fig. 2; P = 0.04). From objective analysis, the clinicians observed a consistent better improvement in Group A than in Group B on clinical conditions (P = 0.02). Frequency, urgency, and odynuria are relieved effectively in Group A (21/64 32.9 %) and in Group B (41/63 65.1 %), with significant difference observed (P = 0.001). No statistical evidence of benefit was observed in terms of recurrence. No obvious hyaluronic acid-related adverse event was observed.

Conclusions

As compared to intravesical instillation of pirarubicin alone, the administration of pirarubicin combined with HA for prevention from postoperative recurrence was satisfactory and safe. The relief of pelvic pain and urinary symptoms is more rapid and more durable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. American Cancer Society (2012) Cancer facts and figures 2012. American Cancer Society, Atlanta

    Google Scholar 

  2. Pashos CL, Botteman MF, Laskin BL, Redaelli A (2002) Bladder cancer. Cancer Pract 10:311–322

    Article  PubMed  Google Scholar 

  3. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD (2004) Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93:485

    Article  CAS  PubMed  Google Scholar 

  4. Avritscher EBC, Cooksley CD, Grossman HB et al (2006) Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68:549–553

    Article  PubMed  Google Scholar 

  5. Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 171(6):2186–2190

    Article  PubMed  Google Scholar 

  6. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008

    Article  PubMed  Google Scholar 

  7. Hall MC, Chang SS, Dalbagni G et al (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 Update. J Urol 178:2314–2330

    Article  PubMed  Google Scholar 

  8. Huland H, Kloppel G, Feddersen I, Otto U, Brachmann W, Hubmann H et al (1990) Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J Urol 144:68

    CAS  PubMed  Google Scholar 

  9. Eijsten A, Knonagel H, Hotz E, Brutsch HP, Hauri D (1990) Reduced bladder capacity in patients receiving intravesical chemoprophylaxis with mitomycin C. Br J Urol 66:386

    Article  CAS  PubMed  Google Scholar 

  10. Ots PMS, Carrizosa CL, Rodríguez A, de Dios Sáez J, Delgado JM, de Miguel MM, Vidal M (2009) Vesical instillations of hyaluronic acid to reduce the acute vesical toxicity caused by high-dose brachytherapy do not affect the survival: a five-year follow-up study. Clin Transl Oncol 11(12):828–834

    Article  Google Scholar 

  11. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29

    Article  PubMed  Google Scholar 

  12. Mostofi FK, Sobin LH, Torloni H (1973) Histological typing of urinary bladder tumors. International histological classification of tumors, vol 10. World Health Organization, Geneva, pp 15–17

    Google Scholar 

  13. Rubben H, Lutzeyer H, Fischer N et al (1988) Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139:283–285

    CAS  PubMed  Google Scholar 

  14. Schilling JD, Mulvey MA, Hultgren SJ (2001) Dynamic interactions between host and pathogen during acute urinary tract infections. Urology 57:56–61

    Article  CAS  PubMed  Google Scholar 

  15. Reid G (1999) Current scientific understanding of urinary tract infections in women: an overview. World J Urol 17:336–338

    Article  CAS  PubMed  Google Scholar 

  16. Gupta K, Stamm WE (1999) Pathogenesis and management of recurrent urinary tract infections in women. World J Urol 17:415–420

    Article  CAS  PubMed  Google Scholar 

  17. Poggi MM, Johnstone PAS, Conner RJ (2000) Glycosaminoglycan content of human bladders: a method of analysis using cold cup biopsies. Urol Oncol 5:234–237

    Article  CAS  PubMed  Google Scholar 

  18. Morales A, Emerson L, Nickel JC (1997) Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. Urology 49:111–113

    Article  CAS  PubMed  Google Scholar 

  19. Parsons CL (1997) Epithelial coating techniques in the treatment of interstitial cystitis. Urology 49:100–104

    Article  CAS  PubMed  Google Scholar 

  20. Daha LK, Riedl CR, Hohlbrugger G, Knoll M, Engelhardt PF, Pflüger H (2003) Comparative assessment of maximal bladder capacity, 0.9% NaCl versus 0.2 M KCl, for diagnosis of interstitial cystitis: prospective controlled study. J Urol 170:807–809

    Article  PubMed  Google Scholar 

  21. Schiavenato M, Craig KD (2010) Pain assessment as a social transaction: beyond the “gold standard”. Clin J Pain 26(8):667–676

    PubMed  Google Scholar 

  22. Topazio L, Miano R, Maurelli V, Gaziev G, Gacci M, Iacovelli V, Finazzi-Agrò E (2014) Could hyaluronic acid (HA) reduce Bacillus Calmette-Guérin (BCG) local side effects? Results of a pilot study. BMC Urol 13(14):64. doi:10.1186/1471-2490-14-64

    Article  Google Scholar 

  23. Li NC, Ye ZQ, Na YQ, CUA THP Immediate Instillations Study Group (2013) Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study. Chin Med J (Engl) 126(15):2805–2809

    PubMed  Google Scholar 

  24. Ito A, Shintaku I, Satoh M et al (2013) Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 31(11):1422–1427. doi:10.1200/JCO.2012.45.2128 (Epub 2013 Mar 4)

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

All authors state that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Graduate School, Southern Medical University, 1023 Shatainan Road, Guangzhou, 510515, Guangdong, People’s Republic of China

    Weiping Huang, Cunzao Wu & Weilie Hu

  2. Department of Urology, The First Affiliated Hospital, Wenzhou Medical University, Nanbaixiang, Ouhai, Wenzhou, Zhejiang Province, People’s Republic of China

    Weiping Huang, Feng Wang & Cunzao Wu

  3. Department of Urology, Guangzhou General Hospital of Guangzhou Military Command, 111 Liuhua Road, Guangzhou, 510010, Guangdong, People’s Republic of China

    Weilie Hu

Authors
  1. Weiping Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Feng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cunzao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weilie Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weilie Hu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, W., Wang, F., Wu, C. et al. Efficacy and safety of pirarubicin combined with hyaluronic acid for non-muscle invasive bladder cancer after transurethral resection: a prospective, randomized study. Int Urol Nephrol 47, 631–636 (2015). https://doi.org/10.1007/s11255-015-0940-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-015-0940-1

Keywords

Search

Navigation